CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells for B-cell Acute Lymphoblastic Leukemia

Phase-Based Progress Estimates
Children's Hospital Colorado, Aurora, COB-cell Acute Lymphoblastic Leukemia+1 MoreCD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells - Drug
30 - 25
All Sexes
What conditions do you have?

Study Summary

This trial will study a new cancer treatment that uses a person's own immune cells to target and kill cancer cells. The treatment will be given to patients who have been previously excluded from other trials, such as children with cancer.

Eligible Conditions
  • B-cell Acute Lymphoblastic Leukemia
  • Non-Hodgkin's Lymphoma

Treatment Effectiveness

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: 5 years

5 years
Non-Relapse Mortality
Overall Survival
Time to Transplant
Up to 21 months
Dose limiting toxicities

Trial Safety

Trial Design

1 Treatment Group

UCD19 CART infusion
1 of 1

Experimental Treatment

50 Total Participants · 1 Treatment Group

Primary Treatment: CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells · No Placebo Group · Phase 1 & 2

UCD19 CART infusion
Experimental Group · 1 Intervention: CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 5 years

Who is running the clinical trial?

University of Colorado, DenverLead Sponsor
1,606 Previous Clinical Trials
1,931,348 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,153 Previous Clinical Trials
41,162,874 Total Patients Enrolled
Amy Keating, MDPrincipal InvestigatorChildren's Hospital Colorado

Eligibility Criteria

Age 30 - 25 · All Participants · 8 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have had cancer come back two or more times or after a stem cell transplant. You have not responded to standard treatment according to your doctor.

Frequently Asked Questions

How many participants have been recruited for this clinical experiment?

"Confirmed, the clinical trial is still open for enrollment. It was first posted on February 24th 2021 with its most recent update occurring November 9th 2022. The project hopes to enroll 50 individuals from 1 medical centre." - Anonymous Online Contributor

Unverified Answer

Does this research have any age restrictions?

"This medical trial is open to participants who are between 30 days and 25 years of age." - Anonymous Online Contributor

Unverified Answer

What requirements must be met in order to enlist for this medical study?

"This clinical trial demands that all participants be between 1 month and 25 years old, with a diagnosis of diffuse lymphoma. Additionally, the total number of patients sought is fifty (50)." - Anonymous Online Contributor

Unverified Answer

Are there still vacancies to take part in this analysis?

"Yes, the website confirms that this research is actively trying to recruit individuals for participation. Initially posted on February 24th 2021 and recently modified on November 9th 2022, this medical trial seeks 50 participants at a single location." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.